Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 110

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Keratin‐18 and micro RNA ‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts

Thulin, Petra, Nordahl, Gunnar, Gry, Marcus, Yimer, Getnet, Aklillu, Eleni, Makonnen, Eyasu, Aderaye, Getachew, Lindquist, Lars, Mattsson, C. Mikael, Ekblom, Björn, Antoine, Daniel J., Park, B. Kevin, Linder, Stig, Harrill, Alison H., Watkins, Paul B., Glinghammar, Björn, Schuppe‐Koistinen, Ina · 2014 · Liver International

Abstract

Background & Aims: There is a demand for more sensitive, specific and predictive biomarkers for drug‐induced liver injury ( DILI ) than the gold standard used today, alanine aminotransferase ( ALT ). The aim of this study was to qualify novel DILI biomarkers (keratin‐18 markers M65/M30, micro RNA ‐122, glutamate dehydrogenase and alpha‐foetoprotein) in human DILI . Methods: Levels of the novel biomarkers were measured by enzyme‐linked immunosorbent assay or real‐time quantitative reverse‐transcription PCR ( qRT ‐PCR) in two human DILI cohorts: a human volunteer study with acetaminophen and a human immunodeficiency virus (HIV)/tuberculosis (TB) study. Results: In the acetaminophen study, serum M65 and micro RNA ‐122 levels were significantly increased at an earlier time point than ALT . Furthermore, the maximal elevation of M65 and micro RNA ‐122 exceeded the increase in ALT . In the HIV / TB study, all the analysed novel biomarkers increased after 1 week of treatment. In contrast to ALT , the novel biomarkers remained stable in a human cohort with exercise‐induced muscular injury. Conclusions: M65 and micro RNA ‐122 are potential biomarkers of DILI superior to ALT with respect to sensitivity and specificity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.12322

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 47

  1. 10.1111/j.1365-2036.2010.04320.x · DOI · Paper page
  2. 10.1172/JCI103055 · DOI · Paper page
  3. Lindena J, 1986, Catalytic enzyme activity concentration in tissues of man, dog, rabbit, guinea pig, rat and mouse. Approach to a quantitative diagnostic enzymology, III. Communication, J Clin Chem Clin Biochem, 24, 35
  4. 10.1111/j.1365-2125.2007.03001.x · DOI · Paper page
  5. 10.1161/01.CIR.11.6.871 · doi:10.1161/01.cir.11.6.871
  6. 10.2337/diabetes.53.11.2855 · DOI · Paper page
  7. 10.2337/diabetes.53.10.2623 · DOI · Paper page
  8. 10.1016/j.taap.2008.03.007 · DOI
  9. 10.1016/j.tox.2007.11.021 · DOI · Paper page
  10. 10.1016/j.drudis.2011.04.011 · DOI
  11. 10.1016/j.jhep.2011.12.019 · DOI · Paper page
  12. 10.1002/hep.24538 · DOI · Paper page
  13. 10.3892/ijmm.2012.1106 · doi:10.3892/ijmm.2012.1106
  14. 10.1002/hep.20511 · DOI · Paper page
  15. Moll R, 1991, Molecular diversity of cytokeratins: significance for cell and tumor differentiation, Acta Histochem Suppl, 41, 117
  16. 10.1073/pnas.0804549105 · DOI · Paper page
  17. 10.1186/1471-2164-8-166 · DOI · Paper page
  18. 10.1016/0009-8981(88)90356-7 · DOI
  19. 10.7326/0003-4819-80-2-156 · doi:10.7326/0003-4819-80-2-156
  20. 10.1002/lt.20886 · DOI
  21. 10.1185/030079906X148346 · DOI
  22. 10.1111/j.1478-3231.2011.02501.x · DOI · Paper page
  23. 10.1111/j.1440-1746.2007.05207.x · DOI · Paper page
  24. 10.1016/j.jhep.2005.11.027 · DOI · Paper page
  25. 10.1164/ajrccm.151.1.7812542 · DOI · Paper page
  26. 10.1038/clpt.2009.240 · DOI
  27. 10.1371/journal.pone.0027810 · DOI
  28. 10.1111/j.1478-3231.2006.01197.x · DOI
  29. 10.1158/1940-6207.CAPR-09-0094 · DOI · Paper page
  30. 10.1007/s00228-010-0862-x · DOI
  31. 10.1002/hep.26294 · DOI · Paper page
  32. 10.1111/j.1478-3231.2011.02528.x · DOI
  33. 10.1038/clpt.2012.40 · DOI · Paper page
  34. 10.1586/erm.10.14 · doi:10.1586/erm.10.14
  35. 10.1371/journal.pone.0037395 · DOI
  36. 10.1177/0192623312464436 · DOI
  37. 10.1373/clinchem.2009.131797 · DOI · Paper page
  38. 10.3748/wjg.v12.i8.1175 · doi:10.3748/wjg.v12.i8.1175
  39. 10.1309/14TY-2TDJ-1X0Y-1V6V · DOI · Paper page
  40. 10.1007/s00421-010-1774-2 · DOI
  41. 10.1080/03602530802341133 · DOI
  42. 10.1002/hep.20548 · DOI · Paper page
  43. Giboney PT, 2005, Mildly elevated liver transaminase levels in the asymptomatic patient, Am Fam Physician, 71, 1105
  44. 10.1046/j.1365-2125.2003.01969.x · DOI
  45. 10.1002/hep.24734 · DOI · Paper page
  46. 10.1371/journal.pone.0023937 · DOI · Paper page
  47. 10.1002/mc.20712 · DOI · Paper page

Cited by

See all 110

Metadata

Authors
Thulin, P., Nordahl, G., Gry, M., Yimer, G., Aklillu, E., Makonnen, E., Aderaye, G., Lindquist, L., Mattsson, C. M., Ekblom, B., Antoine, D. J., Park, B. K., Linder, S., Harrill, A. H., Watkins, P. B., Glinghammar, B., & Schuppe‐Koistinen, I.
Affiliations
  • AstraZeneca R&D Innovative Medicines Personalised Healthcare & Biomarkers Science for Life Laboratory Solna Sweden
  • Former AstraZeneca R&D Global Safety Assessment Molecular Toxicology Södertälje Sweden
  • Department of Pharmacology Faculty of Medicine Addis Ababa University Addis Ababa Ethiopia
  • Division of Clinical Pharmacology Department of Laboratory Medicine Karolinska Institutet Karolinska University Hospital Huddinge Sweden
  • Department of Internal Medicine Faculty of Medicine Addis Ababa University Addis Ababa Ethiopia
  • Department of Medicine Division of Infectious Diseases Karolinska Institutet Karolinska University Hospital Huddinge Sweden
  • Åstrand Laboratory of Work Physiology Swedish School of Sport and Health Sciences Karolinska Institutet Stockholm Sweden
  • MRC Centre for Drug Safety Science Department of Molecular & Clinical Pharmacology University of Liverpool Liverpool UK
  • Department of Oncology‐Pathology Karolinska Institutet Karolinska University Hospital Solna Sweden
  • School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA
  • AstraZeneca R&D Drug Safety & Metabolism Mölndal Sweden
Venue
Liver International
Publisher
Wiley
Published
2013-10-14
Volume
34
Issue
3
Pages
367-378
ISSN
  • 1478-3223
  • 1478-3231
Cited by
110
References
4
Language
en
Funders
  • European and Developing Countries Clinical Trial Partnership (CG_TA.05.40204_005, CT.2005.32030.001)
  • Swedish Research Council (348-2011-7383)
  • National Center for Advancing Translational Sciences
  • National Institutes of Health (UL1TR000083)
  • Medical Research Council (G0700654)
  • Wellcome Trust Research Fellowship

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Keratin‐18 and micro RNA ‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts. https://app.cochat.ai/papers/10.1111/liv.12322
The paper
Thulin, P., Nordahl, G., Gry, M., Yimer, G., Aklillu, E., Makonnen, E., Aderaye, G., Lindquist, L., Mattsson, C. M., Ekblom, B., Antoine, D. J., Park, B. K., Linder, S., Harrill, A. H., Watkins, P. B., Glinghammar, B., & Schuppe‐Koistinen, I. (2014). Keratin‐18 and micro RNA ‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts. Liver International. https://doi.org/10.1111/liv.12322

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.